Clinical Trial Update: Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty [Phase 4]

View source ↗

Summary

Clinical trial investigating losartan to mitigate arthrofibrosis after total joint arthroplasty was withdrawn after Phase 4.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthrofibrosis

Drugs mentioned

• Losartan (losartan)

Snippet

Sponsor: NYU Langone Health | Conditions: Arthrofibrosis | Phase 4 | Status: WITHDRAWN